Genetic manipulation or pharmacological methods have demonstrated that blocking HSP90β can greatly improve obesity-related fatty liver disease, type 2 diabetes, and atherosclerosis by suppressing SREBP function. The gene discussed is HSP90AB1; the disease is fatty liver disease.